新型正电子发射断层扫描放射性药物在放射治疗计划中的应用：概述。
Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.
机构信息
1 Department of Nuclear Medicine and PET-CT, Apollo Gleneagles Hospitals, Kolkata, India ; 2 Department of Nuclear Medicine and PET-CT, Eastern Diagnostics India Ltd., Kolkata, India.
出版信息
Ann Transl Med. 2016 Feb;4(3):53. doi: 10.3978/j.issn.2305-5839.2016.01.26.
Abstract
Positron emission tomography-computed tomography (PET-CT) has changed cancer imaging in the last decade, for better. It can be employed for radiation treatment planning of different cancers with improved accuracy and outcomes as compared to conventional imaging methods. (18)F-fluorodeoxyglucose remains the most widely used though relatively non-specific cancer imaging PET tracer. A wide array of newer PET radiopharmaceuticals has been developed for targeted imaging of different cancers. PET-CT with such new PET radiopharmaceuticals has also been used for radiotherapy planning with encouraging results. In the present review we have briefly outlined the role of PET-CT with newer radiopharmaceuticals for radiotherapy planning and briefly reviewed the available literature in this regard.
摘要
正电子发射断层扫描-计算机断层扫描（PET-CT）在过去十年中改变了癌症影像学，使其变得更好。与传统成像方法相比，它可以用于不同癌症的放射治疗计划，提高准确性和结果。（18）F-氟代脱氧葡萄糖仍然是最广泛使用的但相对非特异性的癌症成像 PET 示踪剂。已经开发了广泛的新型 PET 放射性药物，用于不同癌症的靶向成像。具有这些新型 PET 放射性药物的 PET-CT 也已用于放射治疗计划，并取得了令人鼓舞的结果。在本综述中，我们简要概述了新型放射性药物 PET-CT 在放射治疗计划中的作用，并简要回顾了这方面的现有文献。
相似文献
1
Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.
Ann Transl Med. 2016 Feb;4(3):53. doi: 10.3978/j.issn.2305-5839.2016.01.26.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2.
4
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):2-13. doi: 10.1016/j.ijrobp.2007.06.039. Epub 2007 Sep 14.
5
Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):187-95. doi: 10.1016/j.ijrobp.2006.09.033.
6
Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
J Hepatol. 2018 Aug;69(2):336-344. doi: 10.1016/j.jhep.2018.02.018. Epub 2018 Mar 6.
7
Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):445-51. doi: 10.1016/j.ijrobp.2010.05.050. Epub 2010 Sep 9.
8
Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Invest Radiol. 2016 Jan;51(1):7-14. doi: 10.1097/RLI.0000000000000200.
9
Positron emission tomography for radiation treatment planning.
Strahlenther Onkol. 2005 Aug;181(8):483-99. doi: 10.1007/s00066-005-1422-7.
10
Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Tumour Biol. 2016 Mar;37(3):2999-3007. doi: 10.1007/s13277-015-4113-8. Epub 2015 Sep 29.
引用本文的文献
1
Vitamin-based radiopharmaceuticals for tumor imaging.
Med Oncol. 2023 May 2;40(6):165. doi: 10.1007/s12032-023-02031-8.
2
The cultivation of supply side data science in medical imaging: an opportunity to define the future of global health.
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):436-442. doi: 10.1007/s00259-021-05555-1.
3
Primary and Metastatic Brain Tumours Assessed with the Brain and Torso [F]FDG PET/CT Study Protocol-10 Years of Single-Institutional Experiences.
Pharmaceuticals (Basel). 2021 Jul 26;14(8):722. doi: 10.3390/ph14080722.
4
Value of PET imaging for radiation therapy.
Strahlenther Onkol. 2021 Sep;197(9):1-23. doi: 10.1007/s00066-021-01812-2. Epub 2021 Jul 14.
5
3D printing of radioactive phantoms for nuclear medicine imaging.
EJNMMI Phys. 2020 Apr 22;7(1):22. doi: 10.1186/s40658-020-00292-0.
6
Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment.
World J Gastrointest Oncol. 2017 Jan 15;9(1):21-29. doi: 10.4251/wjgo.v9.i1.21.
本文引用的文献
1
Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Medicine (Baltimore). 2015 May;94(17):e678. doi: 10.1097/MD.0000000000000678.
2
Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.
Tumori. 2014 Nov-Dec;100(6):636-44. doi: 10.1700/1778.19268.
3
(11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1270-9. doi: 10.1007/s00259-014-2734-6. Epub 2014 Mar 6.
4
Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S28-35. doi: 10.1007/s00259-013-2404-0. Epub 2013 Apr 11.
5
Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e691-6. doi: 10.1016/j.ijrobp.2012.01.087. Epub 2012 May 30.
6
Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy.
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):68-73. doi: 10.1016/j.ijrobp.2012.03.021. Epub 2012 May 9.
7
Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.
Radiother Oncol. 2011 Dec;101(3):369-75. doi: 10.1016/j.radonc.2011.07.029. Epub 2011 Aug 27.
8
Dose prescription and treatment planning based on FMISO-PET hypoxia.
Acta Oncol. 2012 Feb;51(2):222-30. doi: 10.3109/0284186X.2011.599815. Epub 2011 Aug 28.
9
Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer.
Radiother Oncol. 2011 May;99(2):193-200. doi: 10.1016/j.radonc.2011.05.005. Epub 2011 May 26.
10
[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
Radiat Oncol. 2011 May 1;6:44. doi: 10.1186/1748-717X-6-44.
Zotero 插件